Literature DB >> 28543041

The added value of cardiac index and pulse pressure variation monitoring to mean arterial pressure-guided volume therapy in moderate-risk abdominal surgery (COGUIDE): a pragmatic multicentre randomised controlled trial.

J Stens1, J-P Hering2, C W P van der Hoeven3, A Boom3, H S Traast4, L E Garmers4, S A Loer1, C Boer1.   

Abstract

There is disagreement regarding the benefits of goal-directed therapy in moderate-risk abdominal surgery. Therefore, we tested the hypothesis that the addition of non-invasive cardiac index and pulse pressure variation monitoring to mean arterial pressure-based goal-directed therapy would reduce the incidence of postoperative complications in patients having moderate-risk abdominal surgery. In this pragmatic multicentre randomised controlled trial, we randomly allocated 244 patients by envelope drawing in a 1:1 fashion, stratified per centre. All patients had mean arterial pressure, cardiac index and pulse pressure variation measured continuously. In one group, healthcare professionals were blinded to cardiac index and pulse pressure variation values and were asked to guide haemodynamic therapy only based on mean arterial pressure (control group). In the second group, cardiac index and pulse pressure variation values were displayed and kept within target ranges following a pre-defined algorithm (CI-PPV group). The primary endpoint was the incidence of postoperative complications within 30 days. One hundred and seventy-five patients were eligible for final analysis. Overall complication rates were similar (42/94 (44.7%) vs. 38/81 (46.9%) in the control and CI-PPV groups, respectively; p = 0.95). The CI-PPV group had lower mean (SD) pulse pressure variation values (9.5 (2.0)% vs. 11.9 (4.6)%; p = 0.003) and higher mean (SD) cardiac indices (2.76 (0.62) l min-1 .m-2 vs. 2.53 (0.66) l min-1 .m-2 ; p = 0.004) than the control group. In moderate-risk abdominal surgery, we observed no additional value of cardiac index and pulse pressure variation-guided haemodynamic therapy to mean arterial pressure-guided volume therapy with regard to postoperative complications.
© 2017 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Keywords:  ASA physical status; arterial waveform; monitored anaesthesia care; patient care; quality measures

Mesh:

Year:  2017        PMID: 28543041     DOI: 10.1111/anae.13834

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  9 in total

1.  Association of conflicts of interest with the results and conclusions of goal-directed hemodynamic therapy research: a systematic review with meta-analysis.

Authors:  Lina Zhang; Feng Dai; Alexandria Brackett; Yuhang Ai; Lingzhong Meng
Journal:  Intensive Care Med       Date:  2018-08-13       Impact factor: 17.440

Review 2.  Automated systems for perioperative goal-directed hemodynamic therapy.

Authors:  Sean Coeckelenbergh; Cedrick Zaouter; Brenton Alexander; Maxime Cannesson; Joseph Rinehart; Jacques Duranteau; Philippe Van der Linden; Alexandre Joosten
Journal:  J Anesth       Date:  2019-09-25       Impact factor: 2.078

Review 3.  Heterogeneous impact of hypotension on organ perfusion and outcomes: a narrative review.

Authors:  Lingzhong Meng
Journal:  Br J Anaesth       Date:  2021-08-12       Impact factor: 9.166

4.  Goal-directed haemodynamic therapy (GDHT) in surgical patients: systematic review and meta-analysis of the impact of GDHT on post-operative pulmonary complications.

Authors:  Ahilanandan Dushianthan; Martin Knight; Peter Russell; Michael Pw Grocott
Journal:  Perioper Med (Lond)       Date:  2020-10-15

5.  Effects of perioperative goal-directed fluid therapy combined with the application of alpha-1 adrenergic agonists on postoperative outcomes: a systematic review and meta-analysis.

Authors:  Shuai Feng; Shuyi Yang; Wei Xiao; Xue Wang; Kun Yang; Tianlong Wang
Journal:  BMC Anesthesiol       Date:  2018-08-17       Impact factor: 2.217

6.  Pleth variability index versus pulse pressure variation for intraoperative goal-directed fluid therapy in patients undergoing low-to-moderate risk abdominal surgery: a randomized controlled trial.

Authors:  Sean Coeckelenbergh; Amélie Delaporte; Djamal Ghoundiwal; Javad Bidgoli; Jean-François Fils; Denis Schmartz; Philippe Van der Linden
Journal:  BMC Anesthesiol       Date:  2019-03-09       Impact factor: 2.217

7.  Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).

Authors:  Sohan Lal Solanki; Sudipta Mukherjee; Vandana Agarwal; Raghu S Thota; Kalpana Balakrishnan; Shagun Bhatia Shah; Neha Desai; Rakesh Garg; Reshma P Ambulkar; Nitin Madhukar Bhorkar; Viplab Patro; Snita Sinukumar; Meenakshi V Venketeswaran; Malini P Joshi; Rajesh Holalu Chikkalingegowda; Vijaya Gottumukkala; Pascal Owusu-Agyemang; Avanish P Saklani; Sanket Sharad Mehta; Ramakrishnan Ayloor Seshadri; John C Bell; Sushma Bhatnagar; Jigeeshu V Divatia
Journal:  Indian J Anaesth       Date:  2019-12-11

8.  Goal-directed haemodynamic therapy during general anaesthesia for noncardiac surgery: a systematic review and meta-analysis.

Authors:  Marie K Jessen; Mikael F Vallentin; Mathias J Holmberg; Maria Bolther; Frederik B Hansen; Johanne M Holst; Andreas Magnussen; Niklas S Hansen; Cecilie M Johannsen; Johannes Enevoldsen; Thomas H Jensen; Lara L Roessler; Peter C Lind; Maibritt P Klitholm; Mark A Eggertsen; Philip Caap; Caroline Boye; Karol M Dabrowski; Lasse Vormfenne; Maria Høybye; Jeppe Henriksen; Carl M Karlsson; Ida R Balleby; Marie S Rasmussen; Kim Pælestik; Asger Granfeldt; Lars W Andersen
Journal:  Br J Anaesth       Date:  2021-12-13       Impact factor: 11.719

Review 9.  Hydroxyethyl starch for perioperative goal-directed fluid therapy in 2020: a narrative review.

Authors:  Alexandre Joosten; Sean Coeckelenbergh; Brenton Alexander; Amélie Delaporte; Maxime Cannesson; Jacques Duranteau; Bernd Saugel; Jean-Louis Vincent; Philippe Van der Linden
Journal:  BMC Anesthesiol       Date:  2020-08-20       Impact factor: 2.217

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.